UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Multiple sclerosis, 2020-11, Vol.26 (13), p.1729-1739

2020

Volltextzugriff (PDF)

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286421993999-1756286421993999

2021

Volltextzugriff (PDF)

Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome

Journal of neurology, 2022-05, Vol.269 (5), p.2560-2572

2022

Volltextzugriff (PDF)

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Multiple sclerosis, 2023-12, Vol.29 (14), p.1795-1807

2023

Volltextzugriff (PDF)

Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study

Multiple sclerosis, 2019-07, Vol.25 (8), p.1162-1169

2019

Volltextzugriff (PDF)

What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?

Multiple Sclerosis International, 2014-01, Vol.2014 (2014), p.819216-5

2014

Volltextzugriff (PDF)

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay

Neurology, 2016-02, Vol.86 (5), p.484

2016

Volltextzugriff (PDF)

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

Blood, 2008-04, Vol.111 (7), p.3439-3441

2008

Volltextzugriff (PDF)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS

Neurology, 2017-02, Vol.88 (9), p.842

2017

Volltextzugriff (PDF)

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report

JAMA neurology, 2015-02, Vol.72 (2), p.159

2015

Volltextzugriff (PDF)

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay

Neurology, 2016-08, Vol.87 (9), p.957

2016

Volltextzugriff (PDF)

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Advances in therapy, 2022-04, Vol.39 (4), p.1810-1831

2022

Volltextzugriff (PDF)

COVID-19 in MS: Initial observations from the Pacific Northwest

Neurology : neuroimmunology & neuroinflammation, 2020-09, Vol.7 (5), p.e783-e783

2020

Volltextzugriff (PDF)

Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results

Bone marrow transplantation (Basingstoke), 2012-07, Vol.47 (7), p.946-951

2012

Volltextzugriff (PDF)

People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary

Neurodegenerative disease management, 2024-07, p.1-7

2024

Volltextzugriff (PDF)

Inflammatory colitis associated with Teriflunomide

Multiple sclerosis and related disorders, 2020-11, Vol.46, p.102480, Article 102480

2020

Volltextzugriff (PDF)

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

Multiple sclerosis, 2012-06, Vol.18 (6), p.825-834

2012

Volltextzugriff (PDF)

Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 – Fatigue (MS) 8a

Multiple sclerosis and related disorders, 2021-09, Vol.54, p.103117-103117, Article 103117

2021

Volltextzugriff (PDF)

Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS

Multiple sclerosis and related disorders, 2020-11, Vol.46, p.102600-102600, Article 102600

2020

Volltextzugriff (PDF)

The validity, responsiveness, and score interpretation of the PROMISnq Physical Function – Multiple Sclerosis 15a short form in multiple sclerosis

Multiple sclerosis and related disorders, 2022-06, Vol.62, p.103753-103753, Article 103753

2022

Volltextzugriff (PDF)

FDG-PET abnormalities leading to the diagnosis of an unusual case of probable neurosarcoidosis

Neurology : neuroimmunology & neuroinflammation, 2018-11, Vol.5 (6), p.e506-e506

2018

Volltextzugriff (PDF)

Brain pathology of a patient 7 years after autologous hematopoietic stem cell transplantation for multiple sclerosis

Journal of the neurological sciences, 2017-02, Vol.373, p.339-341

2017

Volltextzugriff (PDF)

Encephalitis and Myelitis in a Young Woman: Overlap Syndrome, Thyroiditis, and Occult Tumor From the National Multiple Sclerosis Society Case Conference Proceedings

Neurology : neuroimmunology & neuroinflammation, 2021-09, Vol.8 (5)

2021

Volltextzugriff (PDF)

Accelerating international MS care through videoconference-based education and case consultation

Neurology, 2016-07, Vol.87 (1), p.e8

2016

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(44)
Deutsch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study

What Do Healthcare Providers Advise Women with Multiple Sclerosis Regarding Pregnancy?

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report

Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

COVID-19 in MS: Initial observations from the Pacific Northwest

Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results

People with multiple sclerosis help design a tool to measure physical functioning and how it affects their daily lives: a plain language summary

Inflammatory colitis associated with Teriflunomide

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

Standardizing fatigue measurement in multiple sclerosis: the validity, responsiveness and score interpretation of the PROMIS SF v1.0 – Fatigue (MS) 8a

Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS

The validity, responsiveness, and score interpretation of the PROMISnq Physical Function – Multiple Sclerosis 15a short form in multiple sclerosis

FDG-PET abnormalities leading to the diagnosis of an unusual case of probable neurosarcoidosis

Brain pathology of a patient 7 years after autologous hematopoietic stem cell transplantation for multiple sclerosis

Encephalitis and Myelitis in a Young Woman: Overlap Syndrome, Thyroiditis, and Occult Tumor From the National Multiple Sclerosis Society Case Conference Proceedings

Accelerating international MS care through videoconference-based education and case consultation

Suchergebnisse filtern